Penumbra Inc (PEN) Stock Analysis and Metrics

Penumbra

NYSE: PEN

$318.66 ▲ +0.76 (+0.24%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap12.48 Bn

P/E72.97

P/S8.58

Div. Yield0.00

ROIC (Qtr)0.07

Revenue Growth (1y) (Qtr)15.62

Add ratio to table…

About

Penumbra, Inc. is a medical technology company that develops manufactures and markets devices for the treatment of vascular and neurovascular conditions. The firm focuses on thrombectomy embolization and access technologies that enable physicians to remove blood clots and treat related disorders. Its products are used in hospitals and clinics across more than one hundred countries. The company operates within the medical device industry specifically serving the interventional neurology and peripheral vascular markets. Founded in 2004 Penumbra has built a global presence through continuous investment in research development and commercial expansion. The company’s mission centers on improving patient outcomes by delivering safe efficient and easy to use solutions for clot removal and vascular repair.

Penumbra generates revenue primarily from the sale of its thrombectomy embolization and access products to hospitals health care providers and distributors. The company’s thrombectomy portfolio includes systems for peripheral and neuro thrombectomy that use catheter based aspiration and computer assisted vacuum technology. Its embolization and access portfolio features coils delivery catheters and related devices used to block abnormal blood vessels and gain access to target anatomy. Revenue is recognized upon shipment or receipt by the customer with some consigned items recognized when used in a procedure. In addition the company earns income from shipping and handling charges that are billed to customers. Sales are driven by direct relationships with specialist physicians and by a network of distributors that support international markets.

The company operates through the following segments: Thrombectomy and Embolization and Access.

• The Thrombectomy segment encompasses products designed to remove blood clots from the cerebral peripheral and venous systems including the INDIGO system with Lightning Bolt and CAT RX catheters and the Penumbra system with RED SENDit JET ACE BMX and MAX devices along with associated accessories and software algorithms that orchestrate pump and catheter interaction. These tools are intended for use in acute ischemic stroke pulmonary embolism and deep vein thrombosis procedures providing clinicians with an option that uses a small incision and catheter based technique to restore blood flow quickly and safely.

• The Embolization and Access segment includes products for embolizing abnormal vasculature and gaining surgical access such as the RUBY embolization platform LANTERN delivery microcatheter POD system and various coil families including SMART COIL Coil 400 POD400 PAC400 and SwiftPAC as well as delivery catheters like Neuron Neuron MAX BENCHMARK BMX DDC PX SLIM MIDWAY and neurosurgical tools such as the Artemis Neuro Evacuation Device. These products are used to treat aneurysms arteriovenous malformations and peripheral vascular lesions by delivering embolic agents or by creating a pathway for diagnostic and therapeutic catheters.

Penumbra holds a leading position in the thrombectomy market where it competes with several large well capitalized medical device companies that offer clot retrieval and aspiration solutions. The company’s competitive advantages stem from its proprietary computer assisted vacuum technology its broad product families covering both neuro and peripheral applications and its strong focus on clinical evidence and physician training. Additionally Penumbra benefits from a global sales presence in more than one hundred countries and a reputation for innovation that helps it maintain market share despite intense rivalry. The firm’s dedication to continuous product improvement and its ability to launch next generation devices ahead of competitors further strengthen its standing in the industry.

Penumbra serves hospitals health care systems clinics and other medical institutions that perform interventional procedures. Its customers include both public and private healthcare providers who purchase the company’s devices for use in stroke heart attack pulmonary embolism and peripheral artery treatments. While the filing does not disclose specific customer names the majority of revenue is derived from institutional buyers rather than individual consumers. The company also works with group purchasing organizations and integrated delivery networks that aggregate demand across multiple facilities. These relationships help Penumbra achieve broad adoption of its products in diverse geographic markets.

Investment Thesis

▲ Bull case

Penumbra’s strong Q1 2026 financial performance demonstrates underlying business momentum that the market may be underestimating ahead of the Boston Scientific acquisition, with total revenue reaching $374,758,000, representing a 15.6% year-over-year increase driven by robust growth in both thrombectomy and embolization and access segments. The embolization and access business showed particularly strong momentum with 23.8% growth, indicating successful expansion beyond the core thrombectomy franchise into adjacent high-growth markets. This diversification reduces reliance on any single product line and positions the company to capture broader vascular treatment opportunities. The international segment also delivered 16.5% revenue growth, reflecting successful geographic expansion and increasing adoption of Penumbra’s technologies in global markets outside the United States. Furthermore, the company maintained a solid gross margin profile with gross profit of $253,411,000, or 67.6% of revenue, showcasing operational efficiency and pricing power despite ongoing investments in research and development. These fundamentals suggest that Penumbra’s intrinsic value may be underappreciated by investors focused solely on the acquisition premium, as the business continues to execute effectively on its growth strategy with improving scale and profitability metrics ahead of the transaction close.
The pending acquisition by Boston Scientific presents a significant bullish catalyst that extends beyond the immediate transaction value, as it provides Penumbra with access to Boston Scientific’s extensive global commercial infrastructure, including established relationships with healthcare systems and group purchasing organizations that could accelerate market penetration for Penumbra’s innovative products. While management did not emphasize this point in recent communications, the combination could enable faster adoption of Penumbra’s computer assisted vacuum thrombectomy (CAVT) systems in emerging markets where Boston Scientific already has deep distribution networks, potentially unlocking revenue growth that exceeds current analyst expectations. Additionally, Boston Scientific’s stated goal of entering “new, fast-growing segments within the vascular space” suggests strategic intent to invest in and expand Penumbra’s embolization and access portfolio, which grew 23.8% in Q1 2026 and represents a key area of unmet clinical need. The acquisition also mitigates near-term risks related to regulatory scrutiny or competitive pressures, as Boston Scientific’s scale and resources could support Penumbra’s ongoing clinical trial programs like STORM-PE and STRIKE-PE, which are generating compelling evidence for expanded indications in pulmonary embolism treatment. This backing could accelerate guideline adoption and reimbursement expansion, creating a longer-term growth trajectory that the market may not be fully pricing in given the focus on deal completion timing.
Recent clinical trial results from the STORM-PE study provide a powerful but underdiscussed growth driver, demonstrating that patients treated with Penumbra’s computer assisted vacuum thrombectomy (CAVT) plus anticoagulation achieved significantly greater functional improvement at 90 days compared to anticoagulation alone, including walking significantly further and a higher proportion achieving NYHA Class I status with no physical limitations. These patient-centered outcomes are critical because they directly influence quality of life and daily functionality, which are increasingly important metrics in value-based care environments and clinical guideline development. The safety profile remained comparable between treatment arms, with no device-related mortality and no difference in symptomatic PE-recurrence, reinforcing the risk-benefit profile of CAVT as a viable adjunct to standard anticoagulation. This evidence positions Penumbra to expand the addressable market for its products beyond current usage patterns, potentially shifting treatment paradigms for intermediate-high risk pulmonary embolism—a condition affecting an estimated 900,000 Americans annually—and supporting premium pricing and broader hospital adoption. Despite the positive implications, management did not highlight how these results could accelerate reimbursement expansion or guideline changes in recent communications, leaving this catalyst underappreciated by investors focused on near-term financials or acquisition mechanics.

Penumbra’s strong Q1 2026 financial performance demonstrates underlying business momentum that the market may be underestimating ahead of the Boston Scientific acquisition, with total revenue reaching $374,758,000, representing a 15.6% year-over-year increase driven by robust growth in both thrombectomy and embolization and access segments. The embolization and access business showed particularly strong momentum with 23.8% growth, indicating successful expansion beyond the core thrombectomy franchise into adjacent high-growth markets. This diversification reduces reliance on any single product line and positions the company to capture broader vascular treatment opportunities. The international segment also delivered 16.5% revenue growth, reflecting successful geographic expansion and increasing adoption of Penumbra’s technologies in global markets outside the United States. Furthermore, the company maintained a solid gross margin profile with gross profit of $253,411,000, or 67.6% of revenue, showcasing operational efficiency and pricing power despite ongoing investments in research and development. These fundamentals suggest that Penumbra’s intrinsic value may be underappreciated by investors focused solely on the acquisition premium, as the business continues to execute effectively on its growth strategy with improving scale and profitability metrics ahead of the transaction close.
The pending acquisition by Boston Scientific presents a significant bullish catalyst that extends beyond the immediate transaction value, as it provides Penumbra with access to Boston Scientific’s extensive global commercial infrastructure, including established relationships with healthcare systems and group purchasing organizations that could accelerate market penetration for Penumbra’s innovative products. While management did not emphasize this point in recent communications, the combination could enable faster adoption of Penumbra’s computer assisted vacuum thrombectomy (CAVT) systems in emerging markets where Boston Scientific already has deep distribution networks, potentially unlocking revenue growth that exceeds current analyst expectations. Additionally, Boston Scientific’s stated goal of entering “new, fast-growing segments within the vascular space” suggests strategic intent to invest in and expand Penumbra’s embolization and access portfolio, which grew 23.8% in Q1 2026 and represents a key area of unmet clinical need. The acquisition also mitigates near-term risks related to regulatory scrutiny or competitive pressures, as Boston Scientific’s scale and resources could support Penumbra’s ongoing clinical trial programs like STORM-PE and STRIKE-PE, which are generating compelling evidence for expanded indications in pulmonary embolism treatment. This backing could accelerate guideline adoption and reimbursement expansion, creating a longer-term growth trajectory that the market may not be fully pricing in given the focus on deal completion timing.
Recent clinical trial results from the STORM-PE study provide a powerful but underdiscussed growth driver, demonstrating that patients treated with Penumbra’s computer assisted vacuum thrombectomy (CAVT) plus anticoagulation achieved significantly greater functional improvement at 90 days compared to anticoagulation alone, including walking significantly further and a higher proportion achieving NYHA Class I status with no physical limitations. These patient-centered outcomes are critical because they directly influence quality of life and daily functionality, which are increasingly important metrics in value-based care environments and clinical guideline development. The safety profile remained comparable between treatment arms, with no device-related mortality and no difference in symptomatic PE-recurrence, reinforcing the risk-benefit profile of CAVT as a viable adjunct to standard anticoagulation. This evidence positions Penumbra to expand the addressable market for its products beyond current usage patterns, potentially shifting treatment paradigms for intermediate-high risk pulmonary embolism—a condition affecting an estimated 900,000 Americans annually—and supporting premium pricing and broader hospital adoption. Despite the positive implications, management did not highlight how these results could accelerate reimbursement expansion or guideline changes in recent communications, leaving this catalyst underappreciated by investors focused on near-term financials or acquisition mechanics.

▼ Bear case

Penumbra faces significant near-term execution risks related to the pending Boston Scientific acquisition that the market may be overlooking, particularly the potential for employee departures and diversion of management attention during the pendency of the transaction, which could disrupt ongoing product development and commercialization efforts. The company explicitly warned in its forward-looking statements about “potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business,” a risk that is heightened given the substantial premium being offered and the likelihood of key talent evaluating post-acquisition opportunities. This is especially concerning for a company like Penumbra whose innovation-driven model relies heavily on retaining specialized engineering and clinical teams to advance its pipeline of thrombectomy and embolization technologies. Additionally, the decision to withhold full-year 2026 financial guidance and cancel investor calls creates information asymmetry that could mask deteriorating operational trends, as investors lose visibility into quarterly performance metrics that might reveal slowing demand or increasing cost pressures during this transitional period.
The company’s revenue growth, while still positive, shows signs of deceleration when examined through the lens of constant currency adjustments and segment-specific trends, suggesting that underlying demand momentum may be weaker than headline figures indicate. In Q1 2026, international revenue grew 16.5% but the constant currency impact was not disclosed in the quarterly release, making it difficult to assess true organic growth outside the U.S., where currency fluctuations could be flattering reported results. More concerning is the thrombectomy segment’s growth rate of only 12.1% in Q1 2026, which represents a meaningful slowdown from the 15.7% growth reported in Q4 2025 and the 16.2% full-year 2025 growth, indicating potential market saturation or increasing competition in the core franchise. Meanwhile, while embolization and access grew strongly at 23.8%, this comes off a smaller base and may not be sustainable if hospital adoption faces reimbursement hurdles or if competitors introduce competing technologies. The lack of constant currency context in the Q1 release makes it impossible to verify whether this strength is genuine or partially inflated by favorable foreign exchange movements, creating uncertainty about the durability of the growth profile.
Penumbra operates in an increasingly competitive and reimbursement-sensitive environment that poses structural challenges to long-term profitability, a risk that is not being adequately discounted by the market despite the impending acquisition. The company acknowledged in its filings the “inability to achieve or maintain satisfactory pricing and margins” as a material risk, which is particularly relevant given that hospitals are under intense pressure to reduce procedure costs and may push back on premium pricing for innovative thrombectomy systems despite clinical benefits. Additionally, the “significant competition” risk factor remains material, as larger players like Boston Scientific (post-acquisition), Medtronic, and Stryker continue to invest in neurovascular and peripheral thrombectomy technologies, potentially eroding Penumbra’s market share over time. The company’s reliance on clinical trial outcomes to drive guideline changes—such as those from STORM-PE—introduces regulatory and adoption uncertainty, as even positive data does not guarantee swift changes in clinical practice or reimbursement policies, especially in cost-constrained healthcare systems. Furthermore, the potential for “unfavorable outcomes in clinical trials” remains an ever-present risk that could undermine the clinical differentiation of Penumbra’s products, particularly as competitors generate their own evidence to challenge the perceived superiority of CAVT technology in venous and pulmonary thrombectomy applications.

Penumbra faces significant near-term execution risks related to the pending Boston Scientific acquisition that the market may be overlooking, particularly the potential for employee departures and diversion of management attention during the pendency of the transaction, which could disrupt ongoing product development and commercialization efforts. The company explicitly warned in its forward-looking statements about “potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business,” a risk that is heightened given the substantial premium being offered and the likelihood of key talent evaluating post-acquisition opportunities. This is especially concerning for a company like Penumbra whose innovation-driven model relies heavily on retaining specialized engineering and clinical teams to advance its pipeline of thrombectomy and embolization technologies. Additionally, the decision to withhold full-year 2026 financial guidance and cancel investor calls creates information asymmetry that could mask deteriorating operational trends, as investors lose visibility into quarterly performance metrics that might reveal slowing demand or increasing cost pressures during this transitional period.
The company’s revenue growth, while still positive, shows signs of deceleration when examined through the lens of constant currency adjustments and segment-specific trends, suggesting that underlying demand momentum may be weaker than headline figures indicate. In Q1 2026, international revenue grew 16.5% but the constant currency impact was not disclosed in the quarterly release, making it difficult to assess true organic growth outside the U.S., where currency fluctuations could be flattering reported results. More concerning is the thrombectomy segment’s growth rate of only 12.1% in Q1 2026, which represents a meaningful slowdown from the 15.7% growth reported in Q4 2025 and the 16.2% full-year 2025 growth, indicating potential market saturation or increasing competition in the core franchise. Meanwhile, while embolization and access grew strongly at 23.8%, this comes off a smaller base and may not be sustainable if hospital adoption faces reimbursement hurdles or if competitors introduce competing technologies. The lack of constant currency context in the Q1 release makes it impossible to verify whether this strength is genuine or partially inflated by favorable foreign exchange movements, creating uncertainty about the durability of the growth profile.
Penumbra operates in an increasingly competitive and reimbursement-sensitive environment that poses structural challenges to long-term profitability, a risk that is not being adequately discounted by the market despite the impending acquisition. The company acknowledged in its filings the “inability to achieve or maintain satisfactory pricing and margins” as a material risk, which is particularly relevant given that hospitals are under intense pressure to reduce procedure costs and may push back on premium pricing for innovative thrombectomy systems despite clinical benefits. Additionally, the “significant competition” risk factor remains material, as larger players like Boston Scientific (post-acquisition), Medtronic, and Stryker continue to invest in neurovascular and peripheral thrombectomy technologies, potentially eroding Penumbra’s market share over time. The company’s reliance on clinical trial outcomes to drive guideline changes—such as those from STORM-PE—introduces regulatory and adoption uncertainty, as even positive data does not guarantee swift changes in clinical practice or reimbursement policies, especially in cost-constrained healthcare systems. Furthermore, the potential for “unfavorable outcomes in clinical trials” remains an ever-present risk that could undermine the clinical differentiation of Penumbra’s products, particularly as competitors generate their own evidence to challenge the perceived superiority of CAVT technology in venous and pulmonary thrombectomy applications.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password